Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
|Articles|June 23, 2015
2015 PDA/FDA Joint Regulatory Conference
Author(s)Pharmaceutical Technology Editors
Pharmaceutical Technology spoke with Monica Caphart, FDA, and Susan Schniepp, PDA, about the 2015 PDA/FDA Joint Regulatory Conference taking place in Washington, DC, in September.
Advertisement
Monica Caphart, leveraging and collaboration program manager with the Division of Human Resource Development at FDA, and Susan Schniepp, chair of PDA Regulatory Affairs and Quality Advisory Board, spoke with Pharmaceutical Technology about the theme of the 2015 PDA/FDA Joint Regulatory Conference, how legislative tools have improved the quality of drug products, and what attendees can expect from conference sessions and regulatory authority interactions.
The 2015 PDA/FDA Joint Regulatory Conference will take place in Washington, DC, September 28–30, 2015.
Advertisement
Related to this article
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Q&A: Patient-Centric Drug Development Should Start at Product Definition
3
What the Olanzapine Depot Approval Means for CMC Teams
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5